Navigation Links
Neurologix Reports Third Quarter 2010 Financial Results
Date:11/12/2010

Neurologix Quarterly Report on Form 10-Q, with financial statements and management's discussion of operations and results, can be found in the "Investors" section of the Company's website at http://www.neurologix.net.

About NLX-P101Neurologix's investigational AAV (adeno-associated virus) vector gene therapy, NLX-P101, is a novel, non-dopaminergic approach that uses an inhibitory gene (glutamic acid decarboxylase or "GAD") to selectively alter the neural circuitry affected in Parkinson's disease and, thereby, normalize brain physiology.  Neurologix's technology is the only gene therapy strategy currently in development which bypasses the dopamine system.  The Company recently announced positive results with NLX-P101 in a Phase 2 trial for advanced Parkinson's disease.

About NeurologixNeurologix, Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of gene transfer therapies for serious disorders of the brain and CNS.  Neurologix's therapeutic approach is built upon the groundbreaking research of its scientific founders and advisors, whose accomplishments have formed the foundation of gene therapy for neurological illnesses.  The Company's current programs address such conditions as Parkinson's disease, epilepsy, depression and Huntington's disease, all of which are large markets not adequately served by current therapeutic options.  For more information, please visit the Neurologix website at http://www.neurologix.net/.

Cautionary Statement Regarding Forward-Looking StatementsThis news release includes certain statements of the Company that may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and which are made pursuant to the Private Securities
'/>"/>

SOURCE Neurologix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. New Details Presented at the World Parkinson Congress on Neurologixs Successful Phase 2 Trial of Gene Therapy for Parkinsons Disease
2. Research Published in Science Translational Medicine Underscores Value of Depression Gene Therapy License Held by Neurologix
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Spherix Reports Second Quarter Earnings
5. Tapestry Reports Second Quarter 2007 Results
6. Callisto Reports on Second-Quarter 2007 Milestones
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
11. Biopure Reports on Meeting with the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Nevro Corp. (NYSE: NVRO ), a ... solutions for the treatment of chronic pain, today announced ... its common stock consisting of 1,475,506 shares to be ... by certain of its stockholders. In addition, Nevro expects ... up to an additional 590,202 shares of common stock ...
(Date:6/1/2015)... MENLO PARK, Calif. , June ... (OTCQX: DMPI) ("DelMar" and the "Company"), a ... cancer therapies in new orphan drug indications, today ... clinical trial of  VAL-083  (dianhydrogalactitol) in patients with ... deadly form of human brain cancer. ...
(Date:6/1/2015)... 1, 2015 CEFALY Technology , the ... device specifically authorized for use prior to the onset ... new PET trial showing that the Cefaly device returns ... in migraine patients, namely the orbitofrontal cortex and rostral ... which is an imaging test of the brain, used a radioactive substance ...
Breaking Medicine Technology:Nevro Announces Proposed Public Offering of Common Stock 2Nevro Announces Proposed Public Offering of Common Stock 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 2DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 4DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 5DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 6DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 7DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 8New Study Shows CEFALY Returns Normal Metabolic Activity to Brain Areas in Migraine Patients 2
... 2011 /PRNewswire-Asia/ -- Winner Medical Group Inc. (Nasdaq: ... Company"), a leading manufacturer of medical dressings, medical ... PurCotton® products in China, today announced that the ... establish Shenzhen PurCotton E-Commerce Co., Ltd.("PurCotton E-Commerce"), aiming ...
... 29, 2011 Cardium Therapeutics (NYSE Amex: ... compliance plan designed to reestablish compliance with its exchange ... the acquisition of a revenue-generating nutraceutical business designed to ... matter, the Company announced the incorporation of MedPodium Health ...
Cached Medicine Technology:Winner Medical's PurCotton E-Commerce Sets Sail 2Winner Medical's PurCotton E-Commerce Sets Sail 3Winner Medical's PurCotton E-Commerce Sets Sail 4Cardium Provides Update on Exchange Listing and Related Business Matters 2Cardium Provides Update on Exchange Listing and Related Business Matters 3Cardium Provides Update on Exchange Listing and Related Business Matters 4Cardium Provides Update on Exchange Listing and Related Business Matters 5
(Date:6/1/2015)... Garden City, NY (PRWEB) June 02, 2015 ... (NAPW) honors Kathy Everette-Gaines as a 2015-2016 inductee ... She is recognized with this prestigious distinction for ... networking organization exclusively for professional women, boasting more ... Chapters. , “I’m pleased to welcome Kathy into ...
(Date:6/1/2015)... June 02, 2015 Dr. ... SC-based Piedmont Physical Medicine & Rehabilitation, P.A., has ... benefits of stem cell therapy for knees, and ... cases preferred alternative to arthroscopy or knee joint ... practitioner of Neuromusculoskeletal, Vascular and Regenerative Medicine, writes ...
(Date:6/1/2015)... New York, New York (PRWEB) June 01, 2015 ... lawsuits ( http://www.testosteronelawsuithub.com/ ) has amended the Case ... AbbVie, Inc.’s AndroGel testosterone gel. The Amended Order ... District of Illinois on May 29, 2015, directs the ... the Court by August 10, 2015 that outlines parameters ...
(Date:6/1/2015)... 01, 2015 The Delta Dental Foundation ... and organizations in Michigan, Ohio and Indiana for its ... Sept. 30, 2015 has been set. , Across the ... to organizations that specifically focus on children’s oral health ... oral health in adults. Each grant request will be ...
(Date:6/1/2015)... On May 14, 2015, the AFC/Doctors ... Cherry Creek Chamber of Commerce for the grand opening ... typically do not offer primary care services by appointment; ... Urgent Care staff to schedule family care procedures, such ... 7:30 p.m. the center hosted presidents, CEOs, and managers ...
Breaking Medicine News(10 mins):Health News:The National Association of Professional Women Inducts Kathy Everette-Gaines, Community Relations Coordinator, Into its VIP Professional Woman of the Year Circle 2Health News:New Article by Dr. Robert G. Schwartz of Piedmont Physical Medicine & Rehabilitation Looks at Benefits of Stem Cell Therapy for Knees 2Health News:New Article by Dr. Robert G. Schwartz of Piedmont Physical Medicine & Rehabilitation Looks at Benefits of Stem Cell Therapy for Knees 3Health News:Testosterone Lawsuit News: Federal Court Amends Order Governing AndroGel Bellwether Trial Selection 2Health News:Testosterone Lawsuit News: Federal Court Amends Order Governing AndroGel Bellwether Trial Selection 3Health News:Testosterone Lawsuit News: Federal Court Amends Order Governing AndroGel Bellwether Trial Selection 4Health News:Brighter Futures Community Grants Program Seeks to Help Fund Local Oral Health Programs 2Health News:Grand Opening For AFC/Doctors Express Cherry Creek Primary Care Clinic 2
... Honors its own Working Mothers Hurricane Heroes, ... the world,s leading provider of employer-sponsored child care,early ... that were,recently recognized as "100 Best Companies" by ... companies are clients of Bright Horizons,underscoring the critical ...
... , (Monday, October 27, 10:30 AM EST) ,The ... alternative to in-home inspections for identifying asthma and allergy ... of Missouri, Kansas City, MO, selected 50 adult subjects ... list of areas in their home using a disposable ...
... , #7720, PATIENTS, HOME PHOTOS HELP IDENTIFY ASTHMA TRIGGERS, ... in-home photography may be a more cost-effective alternative to ... from Truman Medical Center and the University of Missouri, ... asthma to take photos of a predetermined list of ...
... URAC,s Board of,Directors has approved quality standards ... and Property and Casualty Pharmacy Benefit,Management. The ... Pharmacy Quality,Management(R) suite of products., (LOGO: ... within this suite of programs were developed ...
... ENCINITAS, Calif., Oct. 28 Inspired by ... Feel Beautiful Plastic Surgery in,Encinitas and Carlsbad, ... that creates a more sensuous, sculpted, fit ... incorporates advanced,methods that shape surface contour to ...
... Florida Physicians Group, is Early Adopter in U.S., ... ("Global Med" or the "Company") (OTC Bulletin Board: ... that its Wyndgate Technologies(R) ("Wyndgate") division has,licensed its ... physician group in Brevard County, Florida. The system ...
Cached Medicine News:Health News:Bright Horizons Congratulates 76 Clients Named to Working Mother's 100 Best 2Health News:New research about chronic lung disease presented at CHEST 2008 2Health News:New research about chronic lung disease presented at CHEST 2008 3Health News:New research about chronic lung disease presented at CHEST 2008 4Health News:New research about chronic lung disease presented at CHEST 2008 5Health News:New research about chronic lung disease presented at CHEST 2008 6Health News:New research about chronic lung disease presented at CHEST 2008 7Health News:CHEST 2008: Featured abstracts 2Health News:CHEST 2008: Featured abstracts 3Health News:CHEST 2008: Featured abstracts 4Health News:CHEST 2008: Featured abstracts 5Health News:CHEST 2008: Featured abstracts 6Health News:CHEST 2008: Featured abstracts 7Health News:CHEST 2008: Featured abstracts 8Health News:CHEST 2008: Featured abstracts 9Health News:CHEST 2008: Featured abstracts 10Health News:CHEST 2008: Featured abstracts 11Health News:CHEST 2008: Featured abstracts 12Health News:CHEST 2008: Featured abstracts 13Health News:CHEST 2008: Featured abstracts 14Health News:CHEST 2008: Featured abstracts 15Health News:CHEST 2008: Featured abstracts 16Health News:CHEST 2008: Featured abstracts 17Health News:CHEST 2008: Featured abstracts 18Health News:URAC Introduces New Pharmacy Benefit Management Accreditation for Workers' Compensation and Property and Casualty Programs 2Health News:New Tummy Tuck Technique Increases Sensuality 2Health News:Global Med Technologies(R), Inc. Implements Transfusion Management System in Large Private Physician Owned Laboratory 2Health News:Global Med Technologies(R), Inc. Implements Transfusion Management System in Large Private Physician Owned Laboratory 3Health News:Global Med Technologies(R), Inc. Implements Transfusion Management System in Large Private Physician Owned Laboratory 4
This EIA microplate opens new perspectives in the direct detection of Chlamydia. The choice of microplate immunoenzymatic technology and the use of a monoclonal antibody result in a combination of c...
... of rubella IgG antibody in women prior ... from possible rubella viral infection during pregnancy. ... greatly reduced the incidence of rubella epidemics, ... monitoring of immune status, especially for women ...
... Demonstration of rubella IgG antibody in women ... protection from possible rubella viral infection during ... has greatly reduced the incidence of rubella ... accurate monitoring of immune status, especially for ...
... Every Bard BrachyStar® Needle is designed ... an efficient and clinically effective brachytherapy procedure. ... featuring ultra-sharp tips and polished surfaces for ... of needle configurations and sizes assures an ...
Medicine Products: